Cannabis-based medicinal products: further guidance and information

You can find more guidance and information about cannabis-based medicinal products in the links provided on this page.

National Institute for Health and Care Excellence (NICE):

• Cannabis-based medicinal products
• NICE guideline NG144 (November 2019): prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.
• Technology appraisal guidance on cannabidiol with clobazam for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.

NHS England:

• Cannabis-based products for medicinal use

Royal College of Physicians:

• Recommendations on cannabis-based products for medicinal use

General Medical Council:

• Information for doctors on cannabis-based products for medicinal use and
• Prescribing unlicensed medicines.

Medicines and Healthcare products Regulatory Agency:

• The supply, manufacture, importation and distribution of unlicensed cannabis-based products for medicinal use in humans ‘specials’
• A guide to what is a medicinal product - MHRA Guidance Note 8.

Care Quality Commission:

• CQC’s role in the safer management of controlled drugs.

Legislation:

• The Misuse of Drugs Regulations 2001
• Regulation 16A of the Misuse of Drugs Regulations 2001: further information on ordering, supply and use of cannabis-based medicinal products.
• The Misuse of Drugs (amendments) (cannabis and licence fees) (England, Wales and Scotland) Regulations 2018
• Health and Social Care Act 2008
• Care Quality Commission (Registration) Regulations 2009
• research evidence and guidance from international bodies (such as the European Medicines Agency)
• Interim guidance from professional organisations (such as the Royal College of Physicians, the British Paediatric Neurology Association and the Association of British Neurologists).